Regulatory Strategy for Complex Therapeutic Programs

Regulatory Atelier supports seed-stage, venture-backed, public, and global biopharma teams developing therapies where regulatory strategy materially shapes clinical design, operational feasibility, patient access, and commercial value.

Engagements may range from targeted advisory support to fractional regulatory leadership, development architecture, health authority strategy, diligence support, and execution-ready operating systems.

Regulatory Intelligence & Development Strategy

For teams that need a clear, defensible path from complex science to approvable development strategy.

Regulatory Atelier designs integrated regulatory pathways that align clinical, nonclinical, CMC, safety, quality, and commercial considerations from the earliest stages of development.

Services include:

  • End-to-end regulatory pathway design from IND/CTA through NDA/BLA/MAA, commercialization, and lifecycle management

  • Integrated nonclinical, CMC, clinical, safety, and regulatory strategies for first-in-class and high-complexity assets

  • Global development roadmaps across the US, EU, UK, Canada, Latin America, Japan, and key APAC markets

  • Regulatory intelligence systems that translate evolving FDA, EMA, MHRA, Health Canada, PMDA, ICH, and local expectations into practical development decisions

  • Board, investor, and diligence-ready framing of regulatory risk, timelines, evidence gaps, and value inflection points

  • Program sequencing, gap analysis, and cross-functional strategy across Regulatory, Clinical, CMC, Quality, Safety, Commercial, and Operations

Psychedelic, Neuroplastogen & Controlled-Substance Development

For programs where conventional CNS development models are not enough.

Regulatory Atelier advises teams developing MDMA-derived compounds, ibogaine, psilocybin, DMT, ketamine, non-psychedelic neuroplastogens, and next-generation CNS therapeutics.

Services include:

  • IND/CTA strategy for psychedelic, neuroplastogen, and Schedule I programs across multiple regions

  • FDA, DEA, EMA, MHRA, Health Canada, PMDA, and other agency engagement strategy

  • Controlled-substance strategy, including research registrations, site licensing, quotas, import/export permits, diversion-control plans, storage, accountability, destruction, and chain of custody

  • Trial architecture for complex psychedelic and neuroplastogen studies, including durability, expectancy effects, functional unblinding, rater independence, psychotherapy or psychological-support separation, and functional outcomes

  • Development support for PTSD, treatment-resistant depression, anxiety, suicidality, trauma-related disorders, alcohol use disorder, opioid use disorder, polysubstance use, relapse prevention, and functional recovery

  • Documentation and operations calibrated for health authority review, DEA inspection, site execution, and investor diligence

  • Integration of AI/ML-enabled endpoints, digital measures, and real-world data concepts into credible regulatory narratives

REMS, Site-of-Care & Patient Access Infrastructure

For therapies where approval must be translated into safe, scalable delivery.

High-scrutiny therapies often fail not because the science lacks promise, but because the care model, risk controls, site workflows, distribution pathways, and patient journey were not designed early enough.

Regulatory Atelier helps sponsors build the operational architecture needed for complex treatment models, including supervised dosing, controlled distribution, monitoring, discharge, and follow-up.

Services include:

  • REMS strategy, design, and operationalization

  • Site-of-care models for supervised or high-risk administration

  • Site certification, onboarding, training, documentation, and inspection-readiness systems

  • Patient journey mapping from intake through eligibility, dosing, monitoring, discharge, follow-up, and long-term access

  • Specialty pharmacy, investigational pharmacy, and controlled-distribution workflows

  • Accountability, storage, shipment, destruction, deviation, CAPA, and audit-response systems

  • Cross-functional operating models connecting Regulatory, Clinical Operations, Quality, Safety, CMC, Medical Affairs, Commercial, vendors, and sites

  • Launch-readiness planning for therapies with complex administration, monitoring, or risk-management requirements

Rare Disease, Orphan & Pediatric Strategy

For high-need populations where evidence generation, ethics, feasibility, and access must be planned together.

Regulatory Atelier supports rare, ultra-rare, pediatric, and underserved-population programs where small patient numbers, geographic dispersion, fragile populations, and complex benefit-risk considerations require careful regulatory architecture.

Services include:

  • Orphan designation strategy and applications across the US, EU, UK, Canada, Japan, Latin America, and key APAC markets

  • Development plans for rare and ultra-rare diseases with small, fragile, pediatric, or geographically dispersed populations

  • Pediatric strategy, including PSPs, PIPs, deferral/waiver strategy, and lifecycle alignment

  • Evidence-generation strategies using natural history, external controls, registries, biomarkers, surrogate endpoints, and clinically meaningful outcomes

  • Harmonized rare disease and pediatric plans that preserve global coherence while respecting local regulatory requirements

  • Benefit-risk narratives grounded in clinical practice, ethics, feasibility, and desired labeling outcomes

  • Health authority meeting strategy for early alignment on endpoints, population, study design, and approval pathway

Expedited Programs & Health Authority Engagement

For teams seeking acceleration without sacrificing regulatory credibility.

Regulatory Atelier helps sponsors identify, justify, and operationalize expedited and advanced regulatory pathways while ensuring that acceleration strategies remain evidence-based, inspection-ready, and commercially meaningful.

Services include:

  • Strategy and dossiers for Breakthrough Therapy Designation, RMAT, Fast Track, PRIME, Accelerated Approval, Priority Review, and Priority Review Vouchers

  • FDA meeting packages, briefing books, questions, written responses, and follow-up strategy

  • EMA Scientific Advice strategy and cross-regional briefing alignment

  • MHRA, PMDA, Health Canada, and other global agency interactions

  • Controlled-substance agency interfaces, including DEA registrations, quotas, site inspections, import/export planning, and FDA/DEA alignment

  • Regulatory question strategy designed to generate actionable agency feedback rather than generic responses

  • Board and investor facing interpretation of agency feedback, precedent, development risk, and value inflection points

AI-Ready Regulatory Strategy & Submission Infrastructure

For teams preparing regulatory programs for an AI-enabled review environment.

Regulatory Atelier helps sponsors build documentation, governance, and data structures that are clear, traceable, internally consistent, and defensible across human and AI-enabled review.

Services include:

  • AI-ready regulatory documentation frameworks for submissions, briefing packages, response strategies, and internal governance

  • Submission narratives structured for consistency, traceability, and defensibility across modules and regions

  • Regulatory risk assessments for sponsor use of AI-enabled tools in development, documentation, data review, and decision support

  • Governance strategies to mitigate confidentiality, trade secret, hallucination, bias, and due-process risk

  • Internal operating models for responsible use of AI in regulatory intelligence, document drafting, quality review, and agency-response planning

  • Practical planning for FDA Elsa, agentic AI systems, and emerging regulatory review technologies